Protara Therapeutics Files 8-K with Financial Updates
Ticker: TARA · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1359931
| Field | Detail |
|---|---|
| Company | Protara Therapeutics, Inc. (TARA) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations-update, sec-filing
TL;DR
Protara Therapeutics dropped an 8-K on Aug 6th with financial results. Check it out.
AI Summary
On August 6, 2024, Protara Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Specific financial figures and operational details are available within the full report.
Why It Matters
This filing provides investors with crucial, up-to-date information on Protara Therapeutics' financial health and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Protara Therapeutics, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36694 (filing_id) — SEC File Number
- 20-4580525 (tax_id) — IRS Employer Identification No.
- 345 Park Avenue South Third Floor (address) — Principal executive offices
- New York, NY 10010 (address) — Principal executive offices
- ArTara Therapeutics, Inc. (company) — Former company name
- 20200110 (date) — Date of name change from ArTara Therapeutics, Inc.
- PROTEON THERAPEUTICS INC (company) — Former company name
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report on Protara Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 6, 2024.
In which U.S. state is Protara Therapeutics, Inc. incorporated?
Protara Therapeutics, Inc. is incorporated in Delaware.
What were Protara Therapeutics' former company names?
Protara Therapeutics' former company names were ArTara Therapeutics, Inc. and PROTEON THERAPEUTICS INC.
What is the address of Protara Therapeutics' principal executive offices?
The address of Protara Therapeutics' principal executive offices is 345 Park Avenue South, Third Floor, New York, NY 10010.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-06 08:05:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TARA The Nasdaq Capital M
Filing Documents
- ea0210016-8k_protara.htm (8-K) — 26KB
- ea021001601ex99-1_protara.htm (EX-99.1) — 81KB
- 0001213900-24-065378.txt ( ) — 289KB
- tara-20240806.xsd (EX-101.SCH) — 3KB
- tara-20240806_lab.xml (EX-101.LAB) — 33KB
- tara-20240806_pre.xml (EX-101.PRE) — 22KB
- ea0210016-8k_protara_htm.xml (XML) — 4KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition. On August 6, 2024, Protara Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing regardless of any general incorporation language.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 6, 2024, issued by the Registrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTARA THERAPEUTICS, INC. Date: August 6, 2024 By: /s/ Patrick Fabbio Patrick Fabbio Chief Financial Officer 2